Loading...
Loading...
MOLN| Name | Value |
|---|---|
| Revenues | 3.0M |
| Cost of Revenue | 12.7M |
| Gross Profit | -9.6M |
| Operating Expense | 18.1M |
| Operating I/L | -15.1M |
| Other Income/Expense | 0.3M |
| Interest Income | 0.9M |
| Pretax | -14.8M |
| Income Tax Expense | 0.5M |
| Net Income/Loss | -15.3M |
Molecular Partners AG is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of therapeutic proteins. The company's product candidates include Abicipar for the treatment of neovascular wet age-related macular degeneration and diabetic macular edema, as well as MP0420 for the SARS-CoV-2 virus. Additionally, it develops products for immuno-oncology, tumor-localized immune agonists, and HER2-positive cancers. Molecular Partners AG has collaborations with Novartis AG, Amgen SA, Allergan, Inc., and AbbVie Inc. The company generates revenue through the development, manufacturing, and commercialization of its DARPin-conjugated radioligand therapies and other therapeutic protein products.
